Smoking Nicotine and Heart Health
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.
These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.
In Brief
For a person who already has cardiovascular disease, stopping smoking is not one option among many — it is the single most powerful step available, and its benefit is not diminished by the disease already being present. In people with established coronary heart disease, quitting is associated with roughly a 36 to 40% lower risk of death, a benefit that rivals or exceeds the medications that form the backbone of secondary prevention — statins, beta-blockers, ACE inhibitors, and aspirin.¹,² The benefit is specific and substantial across conditions: lower mortality in heart failure, markedly improved limb outcomes and survival in peripheral artery disease, and reduced mortality and repeat procedures after bypass surgery and stenting.³,⁴,⁵ Two facts remove the most common obstacles to acting on this. First, cessation medications — including nicotine replacement — are safe for the large majority of cardiac patients and far safer than continued smoking, a point established by randomized trials in people with heart disease.⁶,⁷ Second, a cardiac event and hospitalization, frightening as they are, are also the moment when quitting is most achievable and most beneficial, and structured support started in hospital and continued afterward measurably improves success.⁸ This final article in the series brings the evidence together for the people who have the most to gain: those whose hearts are already affected, and for whom quitting still changes everything that follows.
The Most Powerful Step Is Still Available
This series has traced the arc of smoking and the heart: what smoking does to the cardiovascular system, why the dependence is so hard to break, what recovers after quitting, and how to actually do it. This final article addresses the people for whom all of it matters most — those who already have cardiovascular disease.
It is easy for someone with established heart disease to conclude that the damage is done and that quitting now is closing the barn door after the horse has bolted. That conclusion is wrong, and correcting it is the central purpose of this article. The evidence is unambiguous and, for many people, surprising: for a person who already has cardiovascular disease, stopping smoking is the single most effective thing they can do to live longer — more effective than most of the medications they may be taking, and effective no matter how long they have smoked or how advanced their disease. The disease being present does not weaken the case for quitting. It strengthens it.
This is called secondary prevention — preventing further events in someone who already has cardiovascular disease — and it differs from the primary prevention discussed in earlier articles, which concerns people who are still healthy. In secondary prevention, the stakes are higher and the baseline risk is greater, which is precisely why removing the single largest modifiable risk factor produces such a large benefit. This article covers how large that benefit is, how it applies to specific conditions, why the medications that help are safe even in cardiac patients, and how to use a cardiac event as a starting point rather than an ending.
This is the tenth and final article in the series. It draws on everything that came before — the mechanisms from the early articles, the recovery timeline, and the treatment approaches — and applies them to the highest-stakes situation. If a single message survives from the whole series, it is the one this article exists to deliver: it is never too late, and for a heart already affected, quitting is the most powerful medicine available.
Why Quitting Is the Most Powerful Step in Secondary Prevention
The magnitude of the benefit is what makes the case, and it is worth stating precisely.
Among people with established coronary heart disease, those who quit smoking have a substantially lower risk of death than those who keep smoking. The current Cochrane review of this evidence — 68 studies — found that quitting was associated with about a 39% lower risk of cardiovascular death (hazard ratio 0.61) and a 43% lower risk of major adverse cardiovascular events such as heart attack and stroke (hazard ratio 0.57).¹ An earlier landmark review found a 36% reduction in all-cause mortality (relative risk 0.64).² These figures come from cohort studies rather than randomized trials — people cannot be randomly assigned to keep smoking — but they are consistent across dozens of studies, and the 2020 Surgeon General concluded that the relationship between cessation and reduced mortality in coronary heart disease is causal.
To put that magnitude in perspective, this benefit rivals or exceeds that of the medications that form the foundation of secondary prevention. The landmark review made the comparison directly, noting that cessation’s survival benefit is at least as large as therapies such as cholesterol-lowering that receive far more clinical attention.² Statins, beta-blockers, ACE inhibitors, and aspirin are each essential secondary-prevention therapies — and smoking cessation’s effect on survival equals or exceeds each of them individually. No one would tell a heart patient to skip their statin. Quitting smoking belongs in exactly the same category of importance: a first-line, mortality-reducing therapy, not a lifestyle suggestion.
This reframing has real consequences for how quitting should be treated. It is not an optional extra to be mentioned in passing at the end of a cardiology visit. It is one of the most effective interventions available to the patient, and it deserves the same seriousness, the same clinical support, and the same follow-up as a prescription. The benefit also does not require perfection or a long runway: the reductions above come from stopping, and, as Article 4 detailed, the cardiovascular benefits of cessation begin within the first days and grow over the following years. For a person with heart disease, there is no version of “too late” — the sooner the better, but later is still profoundly worthwhile.
The Benefits Are Specific to the Disease
The overall mortality figures are compelling, but the benefit takes a specific form in each of the major cardiovascular conditions, and knowing the specifics makes the case concrete.
Coronary artery disease and after a heart attack. This is where the 36 to 40% mortality reduction applies most directly.¹,² A person who has had a heart attack and quits smoking meaningfully lowers their risk of a second one and of dying — an effect on the same order as, or greater than, the cardiac medications prescribed after the event. Continuing to smoke after a heart attack, by contrast, keeps the artery under the same assault that contributed to the first one.
Heart failure. In patients with a weakened heart muscle — left ventricular dysfunction — smoking independently raises the risk of death and heart-failure hospitalization, and quitting reduces the recurrence of heart failure and heart attack within about three years.³ In a group where intensive medication is used to gain every increment of survival, the benefit of stopping smoking is substantial and too often overlooked.
Peripheral artery disease. In peripheral artery disease — narrowing of the arteries to the legs — smoking is the dominant risk factor, and the stakes include not only heart attack and stroke but the limb itself. Among people with symptomatic peripheral artery disease, quitting was associated with roughly 60% lower all-cause mortality over five years — 14% of those who quit died, versus 31% of those who kept smoking (hazard ratio 0.40) — along with improved amputation-free survival (hazard ratio 0.43).⁴ For this condition, cessation is not just about the heart; it is about keeping the leg and staving off the disease’s most feared outcomes.
After bypass surgery or stenting. A revascularization procedure — bypass surgery or a stent — treats a blockage, but it does not treat the underlying disease that produced it, as earlier articles emphasized. Continuing to smoke accelerates that disease and threatens the result of the procedure. In a 20-year follow-up study, patients who kept smoking after bypass surgery had higher mortality and underwent repeat revascularization more often — about 40% more frequently (relative risk 1.42) — than those who quit.⁵ Quitting is, in effect, part of protecting the investment of a major procedure; smoking undermines it.
Across all of these, the theme is the same: the specific cardiovascular condition a person already has is precisely the reason quitting matters more, not less.
Cessation Medications Are Safe in Cardiac Patients
A specific fear stops many cardiac patients from using the treatments that would help them quit: the worry that cessation medications — especially those containing nicotine — are dangerous for a diseased heart. This fear is understandable but, for the large majority of patients, not supported by the evidence, and letting it prevent treatment is a mistake with real consequences.
The reasoning was set out in Articles 3 and 5: nicotine sustains dependence, but the cardiovascular harm of smoking comes overwhelmingly from combustion products, not from nicotine. Nicotine replacement supplies nicotine without the smoke, at lower and steadier levels than a cigarette delivers. The direct evidence in cardiac patients bears this out. In a randomized trial conducted specifically in patients with established cardiac disease, the nicotine patch did not significantly increase cardiovascular events compared with placebo.⁶ More broadly, the largest randomized safety trial of cessation medications found no increase in major adverse cardiovascular events — heart attack, stroke, or cardiovascular death — with the nicotine patch, varenicline, or bupropion.⁷ The medications that most effectively help people quit are, for most cardiac patients, safe.
Two honest qualifications complete the picture. The immediate aftermath of an acute event — the unstable days around a heart attack — is a period where treatment should be individualized with the cardiology team, since the safety trials generally enrolled stable patients. And any medication decision for a person with heart disease belongs with the clinicians who know their history, particularly given the drug interactions and comorbidities common in this group. But the overriding point stands: the relevant comparison is never against a risk-free alternative, because the alternative is continued smoking, which is far more dangerous than any cessation medication. Withholding effective treatment out of an unfounded fear leaves the patient exposed to the one thing that is genuinely hazardous.
Quitting During and After a Cardiac Event
A heart attack or a hospitalization for heart disease is one of the most frightening experiences a person can have. It is also, paradoxically, one of the best opportunities to quit smoking that will ever arise — and understanding why turns a crisis into a starting point.
The reasons are both psychological and physiological. A cardiac event concentrates the mind on the reality of the disease in a way that abstract warnings never do; it is a genuine moment of motivation. The hospital itself enforces a period of abstinence, meaning a person often arrives at discharge already through the hardest early days of withdrawal. And the physiological benefit of stopping is never more immediate than in the aftermath of an event, when the heart most needs its oxygen supply protected. Clinicians describe this convergence as a “teachable moment,” and the evidence supports acting on it.
What works is not a single conversation at discharge but structured support that begins in the hospital and continues afterward. The Cochrane review of cessation in hospitalized patients found that intensive counseling begun during admission and continued for at least a month after discharge increased quit rates (relative risk 1.37), and that adding nicotine replacement to that counseling raised success further (relative risk 1.54).⁸ In one trial among patients hospitalized with cardiovascular disease, such an intervention also reduced deaths and readmissions over the following two years.⁸ The practical implications are clear: cessation support should start during the hospital stay, not be deferred; it should continue after the person goes home, when the risk of relapse is highest; and it should combine medication with ongoing support, exactly as Articles 5 and 6 describe.
Several further points complete the picture for a cardiac patient. Cardiac rehabilitation is the natural home for cessation after discharge: stopping smoking is one of its core goals, alongside supervised exercise, medication optimization, nutrition, and risk-factor management, and it offers exactly the sustained follow-up the evidence favors. Depression and anxiety are common after a heart attack and can make quitting harder; they deserve attention from the care team in their own right, and addressing them may also help a person stay quit. The home matters too: family members who smoke should be encouraged to quit alongside the patient where possible, since a smoke-free home improves long-term success and, as Article 2 covered, protects everyone in it from secondhand smoke. And for anyone who has already switched completely from cigarettes to e-cigarettes, the priority is to avoid returning to combustible cigarettes, with eventual nicotine cessation as the longer-term goal, as Article 7 discussed.
A cardiac event is the moment when the stakes are clearest and the opportunity is greatest. Used well, the worst day can become the first day.
Common Beliefs vs What the Evidence Shows
Several beliefs keep cardiac patients from taking the step that would help them most.
| Common Belief | What the Evidence Shows |
| “I already have heart disease, so quitting now won’t make much difference.” | Quitting reduces mortality in established coronary disease by roughly 36 to 40% — a benefit rivaling or exceeding the major secondary-prevention medications.¹,² |
| “Nicotine replacement is dangerous for someone with a heart condition.” | In a randomized trial in cardiac patients, the nicotine patch did not increase cardiovascular events; the largest safety trial found no increase in major events with patch, varenicline, or bupropion.⁶,⁷ |
| “There’s no point quitting after a heart attack — the damage is done.” | Quitting after a heart attack lowers the risk of another and of dying, and the aftermath is when the benefit is most immediate.¹,²,⁸ |
| “A stent or bypass fixed my problem, so smoking doesn’t matter as much now.” | Procedures treat a blockage, not the disease; continuing to smoke accelerates it, while quitting reduces mortality and repeat procedures.⁵ |
| “I’ll deal with quitting once I’ve recovered from the hospital stay.” | The hospitalization is the highest-yield moment; support started in hospital and continued after discharge works best.⁸ |
What This Means
For a person who already has cardiovascular disease, the evidence points to one conclusion with unusual clarity: quitting smoking is the single most powerful modifiable step available to extend life, its effect on survival rivals or exceeds the medications they may already take, and the presence of disease is the reason to act rather than a reason to give up. The two most common obstacles both dissolve on inspection — the cessation medications are safe for nearly all cardiac patients and far safer than smoking, and a cardiac event is not the end of the opportunity to quit but the best opening for it. None of this makes quitting easy, and the earlier articles were honest about how hard it is. But for a heart already affected, no other single step returns as much.
What This Means for You
- Treat quitting as your most powerful therapy, because it is. Its effect on survival rivals or exceeds the cardiac medications you may take, and it deserves the same commitment as a prescription — not a footnote at the end of a visit.¹,²
- Don’t let fear of the medications stop you. Nicotine replacement and the other cessation medications are safe for the large majority of cardiac patients and far safer than continuing to smoke; raise any concerns — especially in the period right after an acute event — with your cardiology team rather than defaulting to no treatment.⁶,⁷
- Use a cardiac event as the starting line, not the finish. If you are quitting during or after a hospitalization, ask for cessation support before you leave and make sure it continues afterward, combined with medication — the weeks after discharge are where the effort matters most.⁸
- Involve your care team, and know it is never too late. Whatever your condition — coronary disease, heart failure, peripheral artery disease, or a recent procedure — the benefit of quitting is real, specific, and large, and your clinicians can help you access the medications and support that make it achievable.
A safety note remains essential for this group: sudden chest pain, pressure, or tightness; pain radiating to the arm, jaw, or back; sudden shortness of breath; sudden weakness, numbness, difficulty speaking, facial drooping, or sudden vision loss; a sudden severe headache; or loss of consciousness are potential emergencies — call emergency services immediately. Established heart disease raises the stakes of these symptoms, and they should never be waited out.
How Strong Is the Evidence?
Not all of the conclusions in this article rest on equally certain evidence, and knowing the difference is part of using it well. The table below summarizes how confident the current evidence is in each main conclusion.
| Conclusion | Strength of evidence |
| In coronary heart disease, quitting reduces mortality by roughly 36–40% | High — consistent cohort evidence, judged causal by the Surgeon General¹,² |
| Cessation’s survival benefit rivals or exceeds individual secondary-prevention medications | Moderate to high — indirect comparison across trials² |
| Quitting lowers mortality and hospitalization in heart failure | Moderate — observational³ |
| Quitting improves survival and amputation-free survival in peripheral artery disease | Moderate — observational cohort⁴ |
| Quitting after bypass surgery reduces mortality and repeat revascularization | Moderate — long-term cohort⁵ |
| Cessation medications, including nicotine replacement, do not substantially raise cardiac events in cardiac patients | High — randomized trials⁶,⁷ |
| Hospital-initiated counseling continued after discharge increases quit rates | High — randomized trials⁸ |
Clinical Bottom Line
For a person who already has cardiovascular disease, quitting smoking is the single most powerful step available to extend life — associated with a 36 to 40% lower risk of death in established coronary disease, a benefit that rivals or exceeds statins, beta-blockers, ACE inhibitors, and aspirin.¹,² The benefit is specific and substantial across conditions: lower mortality in heart failure, improved limb outcomes and survival in peripheral artery disease, and reduced death and repeat procedures after bypass and stenting.³,⁴,⁵ The cessation medications that make quitting achievable — including nicotine replacement — are safe for the large majority of cardiac patients and far safer than continued smoking, and a cardiac event is the highest-yield moment to begin, especially with structured support started in hospital and continued afterward.⁶,⁷,⁸ The disease already being present is not a reason to give up on quitting; it is the strongest possible reason to do it, and it is never too late to gain.
Series Conclusion
This completes the Smoking, Nicotine, and Heart Health series. Across ten articles, the evidence has pointed consistently in one direction. Smoking damages the cardiovascular system early and out of proportion to the amount smoked; the dependence behind it is a physical condition, not a character flaw; the body begins to recover as soon as smoking stops; effective medications and support make quitting far more achievable than willpower alone; relapse is a normal part of the process rather than a failure; and even when cardiovascular disease is already established, quitting remains the most powerful step a person can take. The single thread running through all of it is that the trajectory can change — that what a person does from now forward matters more than what has already happened. For the heart, there is no more valuable knowledge than that.
Key Terms
Secondary prevention: Preventing further cardiovascular events in a person who already has cardiovascular disease; distinct from primary prevention, which concerns people still free of disease.
Left ventricular dysfunction: A weakened pumping function of the heart’s main chamber, the defining feature of many forms of heart failure.
Peripheral artery disease: Narrowing of the arteries supplying the limbs, most often the legs, for which smoking is the dominant risk factor and outcomes can include limb loss.
Revascularization: A procedure — bypass surgery or stenting — that restores blood flow through a blocked artery; it treats the blockage but not the underlying disease.
Major adverse cardiovascular event (MACE): A combined measure of cardiovascular death, heart attack, and stroke, used to assess the benefit and safety of treatments.
Teachable moment: A point, such as a cardiac event or hospitalization, when motivation and opportunity to change behavior are unusually high.
References
- Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022;8(8):CD014936. https://doi.org/10.1002/14651858.CD014936.pub2
- Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86–97. https://doi.org/10.1001/jama.290.1.86
- Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37(6):1677–1682. https://doi.org/10.1016/S0735-1097(01)01195-0
- Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg.2014;60(6):1565–1571. https://doi.org/10.1016/j.jvs.2014.08.064
- van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36(3):878–883. https://doi.org/10.1016/S0735-1097(00)00810-X
- Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792–1798. https://doi.org/10.1056/NEJM199612123352402
- Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178(5):622–631. https://doi.org/10.1001/jamainternmed.2018.0397
- Streck JM, Rigotti NA, Livingstone-Banks J, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2024;5(5):CD001837. https://doi.org/10.1002/14651858.CD001837.pub4
HeartBuddi® • Your heart. Own it.